Australia's most trusted
source of pharma news
Posted 28 January 2026 PM
Akamis Bio’s lead oncolytic immunotherapy NG-350A could soon reach Australia, with steps already in motion for Novotech to conduct a clinical trial in patients with locally advanced rectal cancer.
The Gene Technology Regulator received a license application from Novotech to conduct the study in September. Comments are now being sought on the consultation version of the Risk Assessment and Risk Management Plan (RARMP) that has been prepared by the Office of the Gene Technology Regulator (OGTR).

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.